Healthy volunteers receiving subcutaneous ARO-MAPT doses of 2.1 mg/kg and 6.4 mg/kg on days 1, 8, and 15 in the Phase 1/2a trial achieved average cerebrospinal fluid tau reductions of 40% and 69% respectively at day 105.

From the articleArrowhead’s blood-brain barrier tech is ‘arguably better’ than others, analysts say after data dropAlso in Experimental Arrowhead RNAi drug hints at Alzheimer’s benefit, Arrowhead reports positive interim data for Alzheimer’s drug By Investing.com